PMID- 34177562
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210629
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Clinical Outcomes of Tanezumab With Different Dosages for Patient With 
      Osteoarthritis: Network Meta-Analysis.
PG  - 614753
LID - 10.3389/fphar.2021.614753 [doi]
LID - 614753
AB  - Background: Osteoarthritis (OA) high disability rate will increase as people 
      getting older, and is the most prevalent form of arthritis in the future. This 
      study identified the clinical effects of optimum doses of tanezumab for patients 
      with OA. Method: Three electronic databases were searched up until January 15, 
      2021. The mean difference (MD) or odds ratio (OR) was considered an effect 
      measure. The design-by-treatment interaction model was adopted for network 
      meta-analyses. Analyses were conducted using WinBUGS 1.4.3 and R 4.0.5 software. 
      Results: nine publications with 10 studies were included. Compared with placebo 
      in network meta-analysis, except the outcomes of Western Ontario and McMaster 
      Universities Osteoarthritis (WOMAC) stiffness subscale and joints replaced, all 
      dosages of tanezumab in the other effectiveness outcome were superior to placebo, 
      and the difference was statistically significant. However, there was no 
      statistical difference among all different doses of tanezumab. Compared with 
      placebo, except the outcomes of adverse events (AEs) and AEs of abnormal 
      peripheral sensation, all different dosages of tanezumab weren't superior to 
      placebo in the other effectiveness outcome, and the difference was statistically 
      significant. The 10 mg of tanezumab with highest SUCRA had the best effect, but 
      it was associated with a higher safety event. Compared with placebo, except the 
      outcomes of WOMAC stiffness subscale and joints replaced, all dosages of 
      tanezumab in the other effectiveness outcome were superior to placebo, and the 
      difference was statistically significant. Compared with placebo, except for the 
      outcomes of AEs and AEs of abnormal peripheral sensation, all dosages of 
      tanezumab in the other effectiveness outcome were superior to placebo, and the 
      difference was statistically significant. Other direct comparisons showed no 
      statistical difference. Conclusion: This study recommended that clinicians should 
      give priority to the treatment of OA patients with a low dose of 2.5 mg according 
      to the patient's condition and actual situation. If the effect using tanezumab 
      with 2.5 mg is not satisfactory, the increase up to 10 mg should be carefully 
      pondered, because of a more unbalanced risk/benefit ratio.
CI  - Copyright (c) 2021 Hu, Song, Yang, Zhang and Tan.
FAU - Hu, Rui
AU  - Hu R
AD  - Department of Orthopedics, Taihe Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Song, Ya-Feng
AU  - Song YF
AD  - Department of Personnel Office, Taihe Hospital, Hubei University of Medicine, 
      Shiyan, China.
FAU - Yang, Zhi-Yan
AU  - Yang ZY
AD  - Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei 
      University of Medicine, Shiyan, China.
FAU - Zhang, Chao
AU  - Zhang C
AD  - Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei 
      University of Medicine, Shiyan, China.
FAU - Tan, Bo
AU  - Tan B
AD  - Department of Orthopedics, Sichuan Provincial People's Hospital, University of 
      Electronic Science and Technology of China, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20210611
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8232525
OTO - NOTNLM
OT  - WOMAC
OT  - clinical outcomes
OT  - osteoarthritis
OT  - systematic review
OT  - tanezumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/29 06:00
MHDA- 2021/06/29 06:01
PMCR- 2021/06/11
CRDT- 2021/06/28 05:54
PHST- 2020/10/07 00:00 [received]
PHST- 2021/06/01 00:00 [accepted]
PHST- 2021/06/28 05:54 [entrez]
PHST- 2021/06/29 06:00 [pubmed]
PHST- 2021/06/29 06:01 [medline]
PHST- 2021/06/11 00:00 [pmc-release]
AID - 614753 [pii]
AID - 10.3389/fphar.2021.614753 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Jun 11;12:614753. doi: 10.3389/fphar.2021.614753. 
      eCollection 2021.